WO1991009608A1 - Pharmaceutical preparation for controlling pathogenic intestinal bacteria - Google Patents
Pharmaceutical preparation for controlling pathogenic intestinal bacteria Download PDFInfo
- Publication number
- WO1991009608A1 WO1991009608A1 PCT/SE1990/000850 SE9000850W WO9109608A1 WO 1991009608 A1 WO1991009608 A1 WO 1991009608A1 SE 9000850 W SE9000850 W SE 9000850W WO 9109608 A1 WO9109608 A1 WO 9109608A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical preparation
- preparation
- carrier medium
- pharmaceutically acceptable
- acceptable carrier
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
- B01J23/56—Platinum group metals
- B01J23/62—Platinum group metals with gallium, indium, thallium, germanium, tin or lead
- B01J23/622—Platinum group metals with gallium, indium, thallium, germanium, tin or lead with germanium, tin or lead
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1236—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/08—Halides
- B01J27/10—Chlorides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C5/00—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
- C07C5/22—Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by isomerisation
- C07C5/2206—Catalytic processes not covered by C07C5/23 - C07C5/31
- C07C5/226—Catalytic processes not covered by C07C5/23 - C07C5/31 with metals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2521/00—Catalysts comprising the elements, oxides or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium or hafnium
- C07C2521/02—Boron or aluminium; Oxides or hydroxides thereof
- C07C2521/04—Alumina
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2523/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00
- C07C2523/14—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of germanium, tin or lead
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2523/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00
- C07C2523/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals
- C07C2523/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals of the platinum group metals
- C07C2523/42—Platinum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2523/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00
- C07C2523/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals
- C07C2523/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group C07C2521/00 of noble metals combined with metals, oxides or hydroxides provided for in groups C07C2523/02 - C07C2523/36
- C07C2523/56—Platinum group metals
- C07C2523/62—Platinum group metals with gallium, indium, thallium, germanium, tin or lead
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
Definitions
- the present invention relates to a pharmaceutical preparation for controlling pathogenic intestinal bacteria in man and in animals, with a view to preventing and/or treating diarrhoea and other gastrointestinal troubles.
- Diarrhoea and other gastrointestinal troubles caused by pathogenic microorganisms constitute a widespread health problem, which affects in particular tourists travelling abroad, people having received cancer therapy involving antibiotics or radiation, and people working in day nurseries.
- pathogenic intestinal bacteria causing diarrhoea include Salmonella, Shigella, Yersinia, E-coli, Pseudomonas, Clostridium pulpe and sordelli, Stafylo- coccus aureus and Campylobactus . These pathogenic microorganisms adhere to the mucous membranes of the intestine and upset the intestinal function, thereby causing diarrhoea.
- the present invention relates to a preparation for controlling pathogenic microorganisms in man and in animals, with a view to preventing and/or treating diarrhoea and other gastrointestinal troubles, said preparation being characterised by containing a viable microorganism strain in the form of Streptococcus lactis strain Lla in at least one pharmaceutically acceptable carrier medium in which the microorganism retains its viability.
- Streptococcus lactis strains An important reason for the effectiveness of the Streptococcus lactis strains is that some of these secrete bacteriocines which have a specific killing effect on some invading microorganisms.
- the inventive pharmaceutical preparation has a microorganism strain content of 10 6 -10 10 , preferably 10 8 -10 9 , microorganisms/ml of final preparation ready for use.
- the carrier for the microorganism strain is an acidulated or fermented milk product, such as soured milk, ropy milk, yoghourt, kefir and the like.
- the microorganism strain may be used as starter culture when preparing such milk products, which results in acidulated or fermented milk products having an increased content, of the advantageous strain.
- Such a preparation may be administered for prophylactic or curative purposes against diarrhoea and other intestinal infec- tions often affecting infants. Further, it may be given to people who have received cancer therapy involving antibiotics or radiation, as well as to tourists travel ling abroad where the bacterial flora is often different from that at home.
- the preparation may also be in dry form for oral administration, e»g. as capsules, tablets or powder.
- the carrier media used in this case are of conventional type and well-known to the expert in the field.
- the capsules may be resistant to gastric juice, so that the bacteria are protected therefrom and only released in the intestine.
- tablets may be provided with a known coating which is resistant to gastric juice.
- powders may be stirred prior to use in an aqueous liquid, such as water, milk and fruit juice.
- the preparation has proved to be a highly effective prophylactic against various pathogenic intestinal bacteria causing gastrointestinal troubles, such as "tourist diarrhoea".
- the preparation may also be used for treating Salmonella-infected people and animals.
- the preparation may also be adapted for treating animals, in which case the carrier is a suitable animal feed.
- the microorganism should be kept in a freeze-dried state, preferably in skimmed milk in a dark and dry place, or frozen at a temperature of about -70°C.
- the requisite dose of the inventive preparation is determined depending on such factors as the age and general state of the patient, as well as the type and seriousness of the illness.
- Teen skilled in the art will have the competence necessary for determining the suitable dose.
- Another advantage of the invention is that a large overdose of the pharmaceutical preparation hardly involves any risks,at all to the patient.
- the microorganism strain forming part of the inven- tive pharmaceutical preparation was isolated in the following manner.
- a naturally-occurring Streptococcus lactis strain was isolated from a. steepgrass, and examined for its inhibitory effect on pathogenic intestinal bacteria. Seven clones were tested, and one called Lla gave the bes results.
- This microorganism strain which is used in the inventive preparation, was deposited in 1989 at The National Collection of Industrial and Marine Bacteria ( NCIMB ) , Torry Research Station, P . O . Box 31 , 135 Abbey Road, Aberdeen AB9 8DG, Great Britain. Its NCIMB accessio number is 40157.
- the microorganism strain is typed or classified according to the API 20 System (API System, La Balme les Grottes, 38390 Montalieu, Vercieu, France).
- the strain has a weak ⁇ -hemolysis.
- a suitable bouillon is M17, see recipe.
- the strain belongs to the Lancefield N group. Making Soured Milk
- the pharmaceutically acceptable carrier medium for the preparation is soured milk.
- the microorganism Lla according to the invention is allowed to grow in milk for 2-20 h, preferably 4 h. Then, the remaining soured- milk culture is added, which results in further growth, but at a reduced temperature of 21°C, if the temperature was higher at the beginning.
- the content of Lla should be 10 6 -10 1 0 cfu/ml, preferably 10 8 -10 9 cfu/ml. Then, the soured milk is left for 20-24 h, preferably 20 h, whereupon it is cooled and filled into containers.
- the Streptocuccus lactis strain of the invention can be found in the intestine even after 3-5 days.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Fodder In General (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03502116A JP3140049B2 (en) | 1989-12-22 | 1990-12-19 | Pharmaceutical formulations for controlling pathogenic intestinal bacteria |
US07/861,796 US5322686A (en) | 1989-12-22 | 1990-12-19 | Pharmaceutical preparation for controlling pathogenic intestinal bacteria |
CA002070687A CA2070687C (en) | 1989-12-22 | 1990-12-19 | Pharmaceutical preparation for controlling pathogenic intestinal bacteria |
DE69025953T DE69025953T2 (en) | 1989-12-22 | 1990-12-19 | PHARMACEUTICAL PREPARATION FOR CONTROLLING PATHOGENIC INTESTINAL BACTERIA |
EP91901938A EP0506817B1 (en) | 1989-12-22 | 1990-12-19 | Pharmaceutical preparation for controlling pathogenic intestinal bacteria |
FI922825A FI96744C (en) | 1989-12-22 | 1992-06-17 | A method of preparing a pharmaceutical preparation for controlling pathogenic intestinal bacteria |
NO922379A NO303620B1 (en) | 1989-12-22 | 1992-06-17 | Process for the preparation of a pharmaceutical surface preparation for controlling pathogenic microorganisms in humans and animals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8904332A SE465206B (en) | 1989-12-22 | 1989-12-22 | PHARMACEUTICAL PREPARATION FOR COMBATING PATHOGENIC BACKGROUND |
SE8904332-7 | 1989-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991009608A1 true WO1991009608A1 (en) | 1991-07-11 |
Family
ID=20377846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1990/000850 WO1991009608A1 (en) | 1989-12-22 | 1990-12-19 | Pharmaceutical preparation for controlling pathogenic intestinal bacteria |
Country Status (13)
Country | Link |
---|---|
US (1) | US5322686A (en) |
EP (1) | EP0506817B1 (en) |
JP (1) | JP3140049B2 (en) |
AT (1) | ATE135228T1 (en) |
AU (1) | AU641722B2 (en) |
CA (1) | CA2070687C (en) |
DE (1) | DE69025953T2 (en) |
DK (1) | DK0506817T3 (en) |
ES (1) | ES2084806T3 (en) |
FI (1) | FI96744C (en) |
NO (1) | NO303620B1 (en) |
SE (1) | SE465206B (en) |
WO (1) | WO1991009608A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577903A1 (en) * | 1992-07-06 | 1994-01-12 | Societe Des Produits Nestle S.A. | Agent antigastrite contenant lactobacillus acidophilus |
GR1002668B (en) * | 1996-03-15 | 1997-04-14 | N | Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt. |
WO1997035596A1 (en) * | 1996-03-25 | 1997-10-02 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
AT405235B (en) * | 1995-11-02 | 1999-06-25 | Helmut Dr Viernstein | PROBIOTALLY EFFECTIVE FORMULATION |
US10596244B2 (en) | 2008-11-17 | 2020-03-24 | Winclove Holding B.V. | Pharmaceutical preparation comprising a combination of Streptococcus strains and lactobacillus strains |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705152A (en) * | 1990-10-26 | 1998-01-06 | Interprise Limited | Antimicrobial composition |
US5478557A (en) * | 1992-07-29 | 1995-12-26 | The United States Of America, As Represented By The Secretary Of Agriculture | Probiotic for control of salmonella |
US5714378A (en) * | 1995-03-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Navy | Pseudomonas chlororaphis microorganism polyurethane degrading enzyme obtained therefrom and method of using enzyme |
US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
EA005649B1 (en) | 2000-08-11 | 2005-04-28 | Дэвид Р. Уитлок | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
BR0306868A (en) * | 2002-01-11 | 2005-04-12 | David R Whitlock | Compositions including ammonia oxidizing bacteria and methods for using them |
US20050100559A1 (en) * | 2003-11-07 | 2005-05-12 | The Procter & Gamble Company | Stabilized compositions comprising a probiotic |
US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8877178B2 (en) * | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
FR2883131B1 (en) * | 2005-03-16 | 2007-04-27 | Sarl Caribou T G Sarl | PROCESS FOR THE PREPARATION OF KEFIR GRAINS, AND APPLICATION TO PREPARATION FACILITIES FOR ANIMAL BREEDING ANIMALS |
AU2006253006B8 (en) * | 2005-05-31 | 2011-09-15 | Alimentary Health Ltd | Feline probiotic Lactobacilli |
BRPI0611492B1 (en) * | 2005-05-31 | 2021-10-13 | Mars, Incorporated | BIFIDOBACTERIA PROBIOTICS FELINE |
ES2551719T3 (en) | 2007-02-01 | 2015-11-23 | Iams Europe B.V. | Procedure to reduce inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
WO2015160911A2 (en) | 2014-04-15 | 2015-10-22 | Aobiome Llc | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1190386A (en) * | 1966-06-28 | 1970-05-06 | Green Cross Corp | Process for producing the Lactic Acid Bacteria Drugs |
SU1333709A1 (en) * | 1985-11-29 | 1987-08-30 | Всесоюзный Научно-Исследовательский Институт Молочной Промышленности | Streptococcus lactis strain used in ferments for making sour milk products |
JPS62201823A (en) * | 1986-02-28 | 1987-09-05 | Freunt Ind Co Ltd | Material containing beneficial enterobacterium and production thereof |
SU1423586A1 (en) * | 1986-06-09 | 1988-09-15 | Институт Микробиологии И Вирусологии Ан Казсср | Method of preparing ferment for ensilaging fodder |
US5143845A (en) * | 1986-09-03 | 1992-09-01 | Toa Pharmaceutical Co., Ltd. | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria |
JP2612001B2 (en) * | 1987-09-04 | 1997-05-21 | フロイント産業株式会社 | Granules containing useful intestinal bacteria and method for producing the same |
AU4055689A (en) * | 1988-08-03 | 1990-03-05 | Wisconsin Alumni Research Foundation | Biological inoculant effective against aphanomyces |
-
1989
- 1989-12-22 SE SE8904332A patent/SE465206B/en unknown
-
1990
- 1990-12-19 ES ES91901938T patent/ES2084806T3/en not_active Expired - Lifetime
- 1990-12-19 JP JP03502116A patent/JP3140049B2/en not_active Expired - Fee Related
- 1990-12-19 US US07/861,796 patent/US5322686A/en not_active Expired - Fee Related
- 1990-12-19 EP EP91901938A patent/EP0506817B1/en not_active Expired - Lifetime
- 1990-12-19 DE DE69025953T patent/DE69025953T2/en not_active Expired - Fee Related
- 1990-12-19 DK DK91901938.0T patent/DK0506817T3/en active
- 1990-12-19 AU AU70482/91A patent/AU641722B2/en not_active Ceased
- 1990-12-19 AT AT91901938T patent/ATE135228T1/en not_active IP Right Cessation
- 1990-12-19 WO PCT/SE1990/000850 patent/WO1991009608A1/en active IP Right Grant
- 1990-12-19 CA CA002070687A patent/CA2070687C/en not_active Expired - Fee Related
-
1992
- 1992-06-17 NO NO922379A patent/NO303620B1/en not_active IP Right Cessation
- 1992-06-17 FI FI922825A patent/FI96744C/en active
Non-Patent Citations (4)
Title |
---|
Dialog Information Service, File 351, World Patent Index 81-90, Dialog accession number 4635009, Freund SANGYO KK: "Capsules contg. bacteria dispersed in oil or powder - used for treating intestinal diseases etc.", JP 62201823, A, 870905, 8741 (Basic). * |
Dialog Information Services, file 351, World Patent Index 81-90, Dialog accession number 4813235, Dairy Ind Res Inst: "Novel Streptococcus lactis strain - is used for souring milk rapidly to obtain aromatic products", SU 1333709, A, 870830, 8815 (Basic). * |
Dialog Information Services, File 351, World Patent Index 81-90, Dialog accession number 5183522, AS Kaza Microbiolog: "Prepn. of ferment for silaging animal fodder - from specified bacterial cultures, with liquid fractions from each strain used to grow other specified strain", SU 1423586, A, 880915, 8914 (Basic). * |
Dialog Information Services, File 351, World Patent Index 81-90, Dialog accession number 5197777, freund SANGYO KK: "Granules contg. enterically usefull bacteria - comprises mixing bacteria with nutrients etc. granulating with shellac in absolute alcohol soln. and opt. coating", JP 1066124, A, 890313, 8916 (Basic). * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577903A1 (en) * | 1992-07-06 | 1994-01-12 | Societe Des Produits Nestle S.A. | Agent antigastrite contenant lactobacillus acidophilus |
US5578302A (en) * | 1992-07-06 | 1996-11-26 | Nestec S.A. | Treatment of stomach ulcers |
AT405235B (en) * | 1995-11-02 | 1999-06-25 | Helmut Dr Viernstein | PROBIOTALLY EFFECTIVE FORMULATION |
GR1002668B (en) * | 1996-03-15 | 1997-04-14 | N | Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt. |
WO1997034496A2 (en) * | 1996-03-15 | 1997-09-25 | Angelos Kontos | Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt |
WO1997034496A3 (en) * | 1996-03-15 | 1997-11-20 | Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt | |
WO1997035596A1 (en) * | 1996-03-25 | 1997-10-02 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
US5902578A (en) * | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
US10596244B2 (en) | 2008-11-17 | 2020-03-24 | Winclove Holding B.V. | Pharmaceutical preparation comprising a combination of Streptococcus strains and lactobacillus strains |
Also Published As
Publication number | Publication date |
---|---|
DE69025953D1 (en) | 1996-04-18 |
FI922825A0 (en) | 1992-06-17 |
US5322686A (en) | 1994-06-21 |
EP0506817B1 (en) | 1996-03-13 |
JP3140049B2 (en) | 2001-03-05 |
DE69025953T2 (en) | 1996-09-05 |
JPH05502873A (en) | 1993-05-20 |
AU641722B2 (en) | 1993-09-30 |
SE465206B (en) | 1991-08-12 |
FI96744C (en) | 1996-08-26 |
SE8904332D0 (en) | 1989-12-22 |
NO303620B1 (en) | 1998-08-10 |
SE8904332L (en) | 1991-06-23 |
DK0506817T3 (en) | 1996-04-15 |
NO922379L (en) | 1992-08-12 |
ATE135228T1 (en) | 1996-03-15 |
CA2070687C (en) | 2001-04-10 |
CA2070687A1 (en) | 1991-06-23 |
EP0506817A1 (en) | 1992-10-07 |
ES2084806T3 (en) | 1996-05-16 |
AU7048291A (en) | 1991-07-24 |
FI96744B (en) | 1996-05-15 |
NO922379D0 (en) | 1992-06-17 |
FI922825A (en) | 1992-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0506817B1 (en) | Pharmaceutical preparation for controlling pathogenic intestinal bacteria | |
US5709857A (en) | Lactobacillus strains of human origin, their compositons and uses thereof | |
KR100386144B1 (en) | Food or drink product with a disinfection property of helicobacter pylori | |
CN110964657B (en) | Bifidobacterium lactis BL-99 capable of improving immunity and application thereof | |
GB1561169A (en) | Fermented food product | |
CN111548970B (en) | Lactobacillus crispatus capable of preventing and/or treating helicobacter pylori infection | |
AU662601B2 (en) | Probiotic for control of salmonella | |
CN114540243A (en) | Lactobacillus rhamnosus capable of preventing and/or treating helicobacter pylori infection and application thereof | |
EP0271364B1 (en) | Preparation suitable for treating enteric disorders | |
Leal et al. | Bacteriocin production and competitiveness of Lactobacillus plantarum LPCO10 in olive juice broth, a culture medium obtained from olives | |
Torres et al. | Prevalence of Clostridium difficile and its cytotoxin in infants in Mexico | |
JP3995733B2 (en) | Immunostimulatory composition | |
EP4209579A1 (en) | Bifidobacterium inhibiting expression of muscle atrophy gene | |
US7678557B2 (en) | Methods for the accumulation and retention of immune-enhancing, bacterial-derived ribonucleotides (ORN) in bacteria | |
JP2001002578A (en) | Helicobacter pylori-removing medicament | |
US6342366B1 (en) | Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures | |
SU1648975A1 (en) | Bacillus subtilis strain, used for fabricating a dairy product for diathesis, dysbacteriosis and bacterial infections treatment | |
Ebrahimi et al. | Native chicken-derived Lactobacillus spp. strains with high probiotic, cholesterol-assimilation and aflatoxin-degradation capabilities | |
Ducluzeau et al. | Production of an antibiotic substance by Bacillus licheniformis within the digestive tract of gnotobiotic mice | |
JPH03120222A (en) | Adjuvant | |
Yusof et al. | Effect of ragi and Lxxx-lactate-producing cultures on enteric pathogens in a rice-based weaning food | |
RU2101020C1 (en) | Preparation showing immunostimulating effect | |
RU2151797C1 (en) | Strain lactobacillus acidophilus k/ar-0,8 is resistant to antibiotics and salt-resistant antagonist pathogens of intestine infections | |
WO1991011510A1 (en) | Lactobacillus acidophilus f-133, lactic acid bacterium preparation prepared therefrom, and process for preparing the same | |
SU469265A3 (en) | The method of obtaining antibiotic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 922825 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2070687 Country of ref document: CA Ref document number: 1991901938 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1991901938 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991901938 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 922825 Country of ref document: FI |